Perspective Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-11.7M | $-12.3M | $-24.7M | $-10.4M | $-11.1M | $-371.0K | $-3.3M | $-4.1M |
| Depreciation & Amortization | $572.0K | $356.0K | $282.0K | $259.0K | $255.0K | $190.0K | — | $67.0K |
| Depreciation | $570.0K | $346.0K | $262.0K | $259.0K | $245.0K | $180.0K | $70.0K | $68.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $719.0K | $656.0K | $720.0K | $451.0K | $1.2M | $1.4M | $207.0K | $465.0K |
| Net Cash from Operating Activities | $-8.9M | $13.8M | $-9.0M | $-10.1M | $-8.1M | $-9.7M | $-4.3M | $-1.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.0M | $9.1M | $89.0K | $227.0K | $555.0K | $201.0K | $61.0K | $90.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-3.3M | $-47.3M | $-89.0K | $-227.0K | $-573.0K | $25.3M | $6.3M | $-35.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $122.1M | $166.3M | $352.0K | $1.0K | $512.0K | $-80.0K | $0 | $28.0K |
| Net Change in Cash | $109.9M | $132.9M | $-8.7M | $-10.3M | $-8.1M | $15.5M | $2.0M | $-36.9M |
| Free Cash Flow | $-9.9M | $4.8M | $-9.1M | $-10.3M | $-8.6M | $-9.9M | $-4.4M | $-1.9M |